ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2094

Identification of Gout Flare Using an Administrative Claims Based Algorithm

Lindsey MacFarlane1, Daniel H. Solomon1 and Seoyoung C. Kim2, 1Rheumatology, Brigham and Women's Hospital, Boston, MA, 2Division of Rheumatology; Division of Pharmacoepidemiology, Brigham and Women's Hospital, Boston, MA

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Epidemiologic methods and gout, Validity

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 9, 2015

Title: Epidemiology and Public Health III: Risk Factors, Treatment and Outcomes of Gout and OA

Session Type: ACR Concurrent Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose:

Gout is a common inflammatory arthritis characterized by repeated acute flares. The ability to accurately identify gout flares is critical for comparative effectiveness studies of gout treatments. Prior studies use claims data to identify gout flares, however, these algorithms have not been validated. This study aimed to develop and validate a claims-based algorithm to identify gout flares.

Methods:

We identified patients receiving care at an academic medical center between 2006 and 2010 with a diagnosis of gout or hyperuricemia using an electronic medical record-Medicare claims linked dataset. We developed 3 algorithms to identify gout flares: 1) International Classification of Diseases, Ninth Revision (ICD-9) code for gout (274.X) and ≤ 1 dispensing for a gout-related medication including colchicine, nonsteroidal anti-inflammatory drugs, COX-2 selective inhibitors, and oral glucocorticoids ≤ 7 days from the date of gout ICD-9 code. The algorithm was run for any gout-related medication and for the individual medication categories. 2) ICD-9 code for gout and a J code for injectable glucocorticoid or a current procedural terminology (CPT) code for arthrocentesis or joint injection ≤ 7 days from the date of gout ICD-9 visit code. 3) ICD-9 code for gout and a J code for injectable glucocorticoid or a CPT code for arthrocentesis or joint injection on the same day.  Gout flares defined by the algorithms were confirmed through medical record review. Physician documentation of gout flare in the record was considered the gold standard. Positive predictive value (PPV) and 95 % confidence intervals (CI) of the algorithms were calculated. A set of 100 patients with a visit coded for gout but without any gout-related medication, arthrocentisis or injectable glucocorticoid claims was used to identify gout without flare and to calculate the negative predictive value (NPV).

Results:

503 flares were identified using the medication algorithm, and 290 were identified using the procedure ≤ 7 days algorithm. The mean age of the patients in the medication algorithm was 75 (±8) years, and 61% were male. The mean age for the procedure algorithm was 76 (±8) years and 68% were male.  The PPV of medication claims ranged from 50-54%. The PPV of the procedure claims ≤ 7 days was 59%, the same day procedure claim was stronger with a PPV of 68% (Table).  The NPV of the algorithm identifying gout without flare was 88% (95% CI 82, 94).

Table. Positive predictive value of algorithms

 

Algorithm

Records Identified

Confirmed Gout

Confirmed Flare

PPV of Flare Algorithm

 

n

n

n

                               %

(95% CI)

ICD-9 +

medication claim for any gout related medications*

503

498

268

53.3

(48.9, 57.7)

ICD-9 +

medication claim for colchicine

302

300

163

54.0

(48.4, 59.62)

ICD-9 +

medication claim for NSAID/ COX-2 selective inhibitor

174

173

87

50.0

(42.6, 57.4)

ICD-9 +

medication claim for glucocorticoids

270

266

145

53.7

(47.8, 59.7)

ICD-9 + CPT or J code within 7 days

290

287

172

59.3

(53.7, 65.0)

ICD-9 + CPT or J code on same day

196

194

134

68.4

(61.9, 74.9)

95% CI= 95% confidence interval; CI % (CI)ICD-9=International Classification of Diseases, 9thRevision; CPT= Current Procedural Terminology; PPV= Positive Predictive Value; NSAID=non steroidal anti-inflammatory;  * gout-related medications include colchicine, NSAIDs, COX-2 selective inhibitor, and glucocorticoids

 

Conclusion:

Our results suggest that a claims-based algorithm utilizing a combination of diagnosis and procedure codes as well as medications may misclassify patients as having a gout flare and caution should be used in interpreting data using claims-based definition of flares. However, as the NPV was high, the claims-based algorithm may be useful to assess the absence of gout flare or to identify a cohort of gout patients with low disease activity or disease remission.


Disclosure: L. MacFarlane, None; D. H. Solomon, Lilly, 2,Pfizer Inc, 2,AstraZeneca, 2,Amgen, 2,Corrona, 2,Genentech and Biogen IDEC Inc., 2; S. C. Kim, Pfizer Inc, 2,AstraZeneca, 2,Lilly, 2,Genentech and Biogen IDEC Inc., 2.

To cite this abstract in AMA style:

MacFarlane L, Solomon DH, Kim SC. Identification of Gout Flare Using an Administrative Claims Based Algorithm [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/identification-of-gout-flare-using-an-administrative-claims-based-algorithm/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/identification-of-gout-flare-using-an-administrative-claims-based-algorithm/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology